Form 4: Enliven Therapeutics CSO Sells Shares

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, reported the sale of 7,000 shares of common stock through a pre-arranged trading plan.

Summary

• Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of 7,000 shares of common stock.
• The sales occurred on September 19, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
• One transaction involved the sale of 4,870 shares at a weighted average price of $19.1095 per share.
• A second transaction involved the sale of 2,130 shares at a weighted average price of $20.016 per share.
• Following these transactions, Lyssikatos beneficially owns 933,188 shares of common stock, held indirectly through The Lyssikatos Revocable Trust 12/15/2011.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine, pre-planned insider sale of a relatively small portion of holdings, which is common and generally not indicative of strong positive or negative sentiment towards the company's future prospects.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate insider information.
• The sales occurred at relatively strong prices, with weighted averages of $19.1095 and $20.016 per share.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence, although the amount sold is a small fraction of total holdings.

Risks

• No specific company-related risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

NA

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information directly related to broader industry trends or competitive landscape. Insider trading activity is a common occurrence across all industries, with Rule 10b5-1 plans being a standard mechanism for executives to manage personal stock holdings in a compliant manner.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns about immediate negative signals. The amount sold is a small percentage of the officer's total holdings.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this routine insider stock transaction.

Key Dates

Recommendation

The filing details a routine, pre-planned insider sale by the Chief Scientific Officer, Joseph P. Lyssikatos, under a Rule 10b5-1 trading plan. The amount sold (7,000 shares) represents a very small fraction of his total beneficial ownership (933,188 shares remaining). Such transactions are common for executives managing personal finances and are generally not indicative of a significant change in the company's fundamental outlook or a strong signal for immediate investment action. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Enliven Therapeutics, ELVN, Insider Trading, Form 4, Joseph P Lyssikatos, Chief Scientific Officer, Stock Sale, 10b5-1 Plan